Cannabinoid Research: What the Science Actually Says About THC, CBD and Cannabis

Cannabinoid research has expanded considerably over the past several decades. Scientists are studying the chemicals found in Cannabis sativa, synthetic cannabinoids, the body's endocannabinoid system, and potential therapeutic applications of individual cannabinoid compounds.

At the same time, the growing amount of research has created an important problem: scientific evidence is often presented as though all cannabis products and all cannabinoids produce the same effects. They do not.

THC, CBD, pharmaceutical cannabinoids, whole-plant cannabis preparations, and other cannabinoids can have different pharmacological properties. Clinical evidence also differs depending on the medical condition being studied, the dose, formulation, route of administration, study design, and characteristics of the people participating in a study.

This article examines what current research can actually tell us about cannabinoids, while separating established findings from areas where scientists are still investigating unanswered questions.

What Are Cannabinoids?

Cannabinoids are a group of chemical compounds associated with the cannabis plant and cannabinoid signaling systems in the body. The cannabis plant contains hundreds of chemical substances, including cannabinoids and other compounds such as terpenes.

The two cannabinoids most widely recognized and studied are delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD). More than 100 additional cannabinoids have also been identified.

Importantly, the term "cannabinoid" does not automatically mean cannabis. Researchers also study endocannabinoids, which are naturally produced by the body, as well as synthetic cannabinoids created in laboratories.

Why Cannabinoid Research Is More Complicated Than It Appears

One of the central challenges in cannabis science is that researchers are not necessarily studying the same thing from one experiment to another.

A clinical trial may examine purified CBD. Another may examine a THC-containing pharmaceutical preparation. A third may investigate a combination of THC and CBD, while another studies a whole cannabis preparation containing numerous chemical constituents.

These products cannot automatically be treated as interchangeable.

A major systematic review of medical cannabinoids analyzed 152 randomized controlled trials involving 12,123 participants. The researchers found that the strength of evidence varied substantially depending on which cannabinoid and medical condition were being examined.

This is one reason responsible cannabinoid research requires researchers and readers to look beyond the word "cannabis" and identify exactly which cannabinoid, formulation, dose, and condition were studied.

THC Research: What Scientists Know

Delta-9-THC is one of the most extensively studied cannabinoids. It is primarily responsible for the intoxicating effects associated with marijuana.

THC interacts with cannabinoid receptors and can affect perception, cognition, coordination, mood, and other physiological processes. Researchers have also investigated THC-containing medicines for several medical conditions.

THC-related pharmaceutical products have an important place in cannabinoid research because they allow scientists to study a defined active ingredient rather than relying exclusively on variable plant material.

In the United States, the FDA has approved dronabinol, a synthetic form of THC, for specific medical uses including chemotherapy-related nausea and vomiting and appetite stimulation associated with weight loss in people with AIDS.

CBD Research: Different From THC Research

Cannabidiol (CBD) has become one of the most heavily researched cannabinoids outside of THC.

CBD does not produce the same intoxicating effects associated with THC, but that does not mean that CBD is biologically inactive. Researchers are studying how CBD interacts with biological systems and how it may influence neurological, physiological, and pharmacological processes.

The strongest established example of CBD's medical application is its use in an FDA-approved prescription medicine.

The FDA has approved Epidiolex, which contains purified CBD, for seizures associated with Lennox-Gastaut syndrome and Dravet syndrome in patients two years of age and older.

This distinction is important. Evidence supporting a purified, prescription CBD medicine for specific seizure disorders does not automatically establish that every commercially available CBD product will have the same effects.

What Does Clinical Cannabinoid Research Actually Show?

The evidence is strongest for certain specific medical applications rather than for cannabis as a universal treatment.

According to the National Center for Complementary and Integrative Health, cannabinoid-based medicines may be useful for certain rare forms of epilepsy, chemotherapy-associated nausea and vomiting, and appetite and weight loss associated with HIV/AIDS. Research also suggests modest benefits for some people with chronic pain and multiple-sclerosis symptoms.

However, evidence for other conditions remains limited, inconsistent, or preliminary.

Cannabinoid Research and Chronic Pain

Chronic pain is one of the most heavily researched areas in cannabinoid science.

Systematic reviews have identified evidence that some cannabinoid medicines can provide pain relief for certain patients. However, the magnitude of the benefit can be modest, and adverse effects occur more frequently in some cannabinoid treatment groups than in placebo groups.

A systematic review of systematic reviews found that cannabinoids may provide benefits for chronic pain, but also emphasized limitations in the evidence, including differences in study size, study duration, formulations, and adverse effects.

Another important issue is that evidence from acute pain research should not automatically be applied to chronic pain. Different types of pain involve different biological mechanisms, and research results cannot simply be transferred from one condition to another.

Cannabinoids and Multiple Sclerosis

Multiple sclerosis is another area in which cannabinoid research has produced clinically relevant findings.

Researchers have studied THC, CBD, combinations of THC and CBD, synthetic cannabinoids, and cannabis-derived preparations for symptoms including spasticity and pain.

Research summarized by NCCIH indicates that cannabinoids may provide some improvement in subjective spasticity symptoms and pain in people with multiple sclerosis. However, objective measurements of muscle spasticity have not always shown the same degree of improvement.

This distinction demonstrates why researchers use multiple outcome measures. A patient's perception of symptom improvement and a clinician's objective measurement can sometimes produce different results.

Cannabinoid Research and Epilepsy

Epilepsy represents one of the clearest examples of cannabinoid research progressing from laboratory investigation to an FDA-approved cannabinoid medicine.

Purified CBD has been studied extensively in severe childhood-onset epilepsy syndromes. The FDA approved Epidiolex for seizures associated with Lennox-Gastaut syndrome and Dravet syndrome.

That approval represents evidence for a specific pharmaceutical product and specific medical indications. It should not be interpreted as proof that cannabis or nonprescription CBD products are effective treatments for every type of seizure disorder.

What About Cannabinoids for Cancer?

Cannabinoid research involving cancer covers several different questions, and they should not be confused.

One area involves cannabinoid medicines for symptoms associated with cancer treatment, particularly nausea and vomiting caused by chemotherapy. Another area involves research into whether cannabinoids themselves could influence cancer biology.

These are fundamentally different research questions.

There is established evidence supporting certain cannabinoid medicines for chemotherapy-associated nausea and vomiting. By contrast, laboratory findings involving cannabinoids and cancer cells do not automatically demonstrate that cannabinoids treat cancer in humans.

Researchers must distinguish laboratory experiments, animal studies, observational research, and controlled clinical trials before drawing conclusions about cancer treatment.

The Endocannabinoid System

A major reason cannabinoid research has expanded beyond cannabis itself is the discovery and study of the endocannabinoid system.

The endocannabinoid system is a biological signaling network involving endogenous cannabinoids, cannabinoid receptors, and enzymes that produce and break down these signaling molecules.

Scientists are studying this system because cannabinoid signaling appears to participate in numerous physiological processes.

NIH-supported cannabinoid research includes investigations into cannabinoid signaling, the endocannabinoid system, cannabinoid receptors, synthetic cannabinoids, phytocannabinoids, and compounds that modify cannabinoid-related pathways.

Understanding these biological mechanisms could eventually help researchers develop medicines that target specific cannabinoid pathways without necessarily producing all of the effects associated with cannabis.

Minor Cannabinoids Are an Important Research Area

THC and CBD receive most of the public attention, but cannabinoid research extends far beyond these two compounds.

Researchers are investigating cannabinoids including cannabigerol (CBG), cannabichromene (CBC), cannabinol (CBN), tetrahydrocannabivarin (THCV), and others.

However, an important scientific limitation remains: relatively few minor cannabinoids have been studied as extensively as THC and CBD.

Laboratory findings can identify interesting biological activity, but additional research is needed to determine whether those effects translate into meaningful and safe outcomes in humans.

Why Terpenes Also Appear in Cannabinoid Research

Cannabis contains compounds other than cannabinoids, including terpenes. Terpenes contribute to the characteristic aromas and flavors associated with different cannabis varieties.

Some researchers are investigating whether terpenes have biological effects of their own and whether they interact with cannabinoids.

However, claims about specific cannabinoid-terpene combinations producing predictable medical effects require clinical evidence. Laboratory observations and theoretical mechanisms should not be presented as established clinical outcomes.

Cannabinoid Research and the "Entourage Effect"

The term entourage effect is frequently used when discussing the possibility that cannabinoids and other cannabis compounds may interact to produce effects that differ from isolated compounds.

This remains an area of scientific investigation.

The existence of multiple compounds in cannabis does not by itself prove that every combination produces a clinically meaningful synergistic effect. Researchers need controlled experiments to determine whether combinations provide benefits beyond the individual components.

Consequently, cannabinoid research continues to examine whether particular combinations of THC, CBD, minor cannabinoids, terpenes, and other compounds produce reproducible differences in humans.

Safety Is Part of Cannabinoid Research

Understanding potential benefits is only one part of cannabinoid science. Researchers also study adverse effects, drug interactions, impairment, dependence, and other safety concerns.

THC can produce intoxication and can affect cognitive and psychomotor performance. Researchers have also documented effects such as anxiety, paranoia, and other psychological or physiological reactions in some circumstances.

CBD also is not completely free of potential adverse effects. NCCIH reports that CBD can be associated with gastrointestinal symptoms, changes in alertness or mood, liver-related effects, and interactions with other medications.

The safety profile of a purified prescription cannabinoid should also not automatically be assumed to apply to an unregulated commercial cannabis or CBD product.

Why Product Quality Matters to Cannabinoid Research

Scientific studies generally depend on knowing what participants actually received.

Commercial cannabis and cannabinoid products can vary in cannabinoid concentrations and may contain contaminants or amounts of cannabinoids that differ from their labels.

This creates an important research and consumer-information issue. If two products labeled with the same cannabinoid concentration contain substantially different amounts of active compounds, comparing their effects becomes more difficult.

Product consistency is therefore an important consideration in both clinical research and interpretation of real-world cannabis studies.

Route of Administration Can Change the Research Results

Another important variable in cannabinoid research is how a cannabinoid enters the body.

Inhaled cannabinoids and orally consumed cannabinoids do not necessarily behave identically. Oral cannabinoids pass through the gastrointestinal tract and liver before reaching systemic circulation, which can substantially alter their metabolism.

Research supported by NCCIH has demonstrated that the interaction between THC and CBD can also depend on the route of administration. In one controlled study involving oral administration, participants who consumed THC with CBD experienced stronger effects than participants who consumed the same THC dose alone. The researchers attributed this in part to CBD's interference with THC metabolism.

This is another reason why cannabinoid research must specify the formulation and route of administration rather than simply reporting that a study involved "cannabis."

What Cannabinoid Research Has Not Established

Scientific evidence does not currently support treating cannabinoids as a universal solution for every medical condition.

Research also does not justify assuming that positive laboratory findings automatically translate into effective human treatments.

Similarly, evidence supporting one cannabinoid does not establish the effectiveness of another cannabinoid. Evidence for purified CBD does not automatically establish the effectiveness of a full-spectrum cannabis product, and evidence for THC-containing pharmaceutical preparations does not automatically establish the same outcome for every cannabis product.

This distinction is essential when evaluating cannabinoid-related health claims.

The Difference Between Preclinical and Clinical Cannabinoid Research

Preclinical research includes laboratory and animal studies. These experiments can help researchers understand mechanisms and identify possible therapeutic targets.

Clinical research studies humans. Randomized controlled trials can help determine whether a treatment produces a measurable effect compared with a placebo or another treatment.

Both types of research are important, but they answer different questions.

A cannabinoid that kills cancer cells in a laboratory dish, for example, has not thereby been demonstrated to treat cancer in humans. Additional stages of research are necessary to determine appropriate dosing, pharmacology, safety, effectiveness, and clinical usefulness.

Why Randomized Controlled Trials Matter

Randomized controlled trials can reduce several sources of bias by randomly assigning participants to treatment or comparison groups.

Systematic reviews and meta-analyses can then combine evidence from multiple studies, although the reliability of their conclusions still depends on the quality and consistency of the underlying research.

A major pharmacology-based systematic review of medical cannabinoids analyzed 152 randomized controlled trials and found substantial variation in the quality and strength of evidence across cannabinoid types and medical conditions.

The lesson is straightforward: the existence of a large body of cannabinoid research does not mean that every proposed use has equally strong evidence.

What Researchers Are Studying Now

NIH-supported research encompasses a broad range of cannabinoid-related questions.

Current research areas include cannabinoid signaling, the endocannabinoid system, minor cannabinoids, synthetic cannabinoids, cannabis constituents, potential therapeutic applications, cannabis use disorder, public health outcomes, and the effects of cannabis exposure across different stages of life.

Researchers are also investigating ways to better understand cannabinoid pharmacology and develop treatments that target specific biological pathways.

These efforts could eventually lead to medicines that are more predictable than complex plant-based preparations.

The Future of Cannabinoid Research

The future of cannabinoid science will likely depend on more precise research rather than simply more research.

Scientists need studies that clearly identify the cannabinoid being tested, its concentration, formulation, route of administration, duration of treatment, patient population, and clinical outcome.

Longer studies are also important because many clinical trials have relatively short treatment periods. Long-term safety and effectiveness cannot always be determined from short-duration studies.

Research into minor cannabinoids and cannabinoid combinations may also expand as analytical and pharmaceutical technologies improve.

The Bottom Line on Cannabinoid Research

Cannabinoid research is a legitimate and rapidly developing area of biomedical science, but the evidence is not uniform.

Some cannabinoid-based medicines have demonstrated clinical value for specific conditions and have received FDA approval. Other potential applications remain under investigation, with evidence ranging from promising preliminary findings to insufficient or inconsistent data.

The most scientifically responsible way to evaluate cannabis and cannabinoid claims is to ask several questions: Which cannabinoid was studied? What formulation was used? What dose was given? How was it administered? What condition was being treated? Was the study conducted in humans? How large was the study? Was there a placebo or comparison group? What were the adverse effects? And can the findings be reproduced?

Those questions matter because cannabinoid research is not one single body of evidence. It is a broad scientific field encompassing many different compounds, mechanisms, products, medical conditions, and research methods.

As the scientific literature continues to grow, distinguishing established findings from preliminary research will remain essential for understanding what cannabinoids can—and cannot—currently tell us about human health.

Frequently Asked Questions About Cannabinoid Research

What is cannabinoid research?

Cannabinoid research is the scientific study of cannabinoids, the endocannabinoid system, cannabis constituents, synthetic cannabinoids, their biological effects, potential therapeutic applications, and potential risks.

What are the two most studied cannabinoids?

THC and CBD are the two most widely recognized and extensively studied cannabinoids. THC is primarily responsible for cannabis's intoxicating effects, while CBD does not produce the same intoxicating effects.

Is cannabinoid research scientifically established?

Yes, cannabinoid research is an established scientific field. However, the strength of evidence differs considerably between cannabinoids, medical conditions, formulations, and study designs.

Does research prove that cannabis treats every medical condition?

No. Research supports some specific medical applications of cannabinoid-based medicines, while evidence for many other proposed applications remains limited or inconclusive.

Is CBD FDA approved?

A purified CBD prescription medicine, Epidiolex, is FDA approved for seizures associated with Lennox-Gastaut syndrome and Dravet syndrome. This approval does not apply to all commercially available CBD products.

Is THC medically studied?

Yes. THC is one of the most extensively studied cannabinoids. Synthetic THC, including dronabinol, has FDA-approved medical uses for specific conditions.

Why do cannabinoid research studies sometimes disagree?

Studies may use different cannabinoids, doses, formulations, routes of administration, patient populations, outcome measurements, and study designs. These differences can produce different results.

What is the endocannabinoid system?

The endocannabinoid system is a biological signaling network involving endogenous cannabinoids, cannabinoid receptors, and enzymes that regulate cannabinoid signaling. It is an important area of ongoing cannabinoid research.

Sources and Further Reading

1. National Center for Complementary and Integrative Health (NCCIH), Cannabis (Marijuana) and Cannabinoids: What You Need To Know.

2. FDA, FDA and Cannabis: Research and Drug Approval Process.

3. Hoch et al., Medical cannabinoids: a pharmacology-based systematic review and meta-analysis for all relevant medical indications, BMC Medicine.

4. Nugent et al., The efficacy and safety of medical cannabinoids for pain, spasticity, and nausea and vomiting, systematic review evidence.

5. National Institutes of Health/NCCIH, NIH-Supported Research on Cannabis, Cannabinoids, and Related Compounds.